DE60144366D1 - Neuroprotektive, antithrombotische und anti-entzündliche anwendungen von aktiviertem protein c - Google Patents
Neuroprotektive, antithrombotische und anti-entzündliche anwendungen von aktiviertem protein cInfo
- Publication number
- DE60144366D1 DE60144366D1 DE60144366T DE60144366T DE60144366D1 DE 60144366 D1 DE60144366 D1 DE 60144366D1 DE 60144366 T DE60144366 T DE 60144366T DE 60144366 T DE60144366 T DE 60144366T DE 60144366 D1 DE60144366 D1 DE 60144366D1
- Authority
- DE
- Germany
- Prior art keywords
- disease
- diseases
- vascular
- activated protein
- brain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000003110 anti-inflammatory effect Effects 0.000 title 1
- 230000000324 neuroprotective effect Effects 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 230000002757 inflammatory effect Effects 0.000 abstract 2
- 208000019553 vascular disease Diseases 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000014644 Brain disease Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 201000009906 Meningitis Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000018262 Peripheral vascular disease Diseases 0.000 abstract 1
- 101800004937 Protein C Proteins 0.000 abstract 1
- 102000017975 Protein C Human genes 0.000 abstract 1
- 229940096437 Protein S Drugs 0.000 abstract 1
- 102000029301 Protein S Human genes 0.000 abstract 1
- 108010066124 Protein S Proteins 0.000 abstract 1
- 101800001700 Saposin-D Proteins 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 208000025698 brain inflammatory disease Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 206010014599 encephalitis Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000006764 neuronal dysfunction Effects 0.000 abstract 1
- 230000002981 neuropathic effect Effects 0.000 abstract 1
- 229960000856 protein c Drugs 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4866—Protein C (3.4.21.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6464—Protein C (3.4.21.69)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21069—Protein C activated (3.4.21.69)
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Neurosurgery (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18022700P | 2000-02-04 | 2000-02-04 | |
| PCT/US2001/003758 WO2001056532A2 (en) | 2000-02-04 | 2001-02-05 | Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE60144366D1 true DE60144366D1 (de) | 2011-05-19 |
Family
ID=22659693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60144366T Expired - Lifetime DE60144366D1 (de) | 2000-02-04 | 2001-02-05 | Neuroprotektive, antithrombotische und anti-entzündliche anwendungen von aktiviertem protein c |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7074402B2 (de) |
| EP (1) | EP1255556B1 (de) |
| JP (1) | JP2004508280A (de) |
| AT (1) | ATE504310T1 (de) |
| AU (1) | AU2001238034A1 (de) |
| CA (1) | CA2398929C (de) |
| DE (1) | DE60144366D1 (de) |
| WO (1) | WO2001056532A2 (de) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040096443A1 (en) * | 2002-03-08 | 2004-05-20 | Traynelis Stephen Francis | Treatment of neurodegenerative diseases and conditions using par1 antagonists |
| ES2384099T3 (es) | 2001-06-13 | 2012-06-29 | The University Of Sydney | Proteína C para cicatrización de heridas |
| US20030073636A1 (en) * | 2001-09-19 | 2003-04-17 | Oklahoma Medical Research Foundation | Method of treating diabetes |
| EP1572134B1 (de) * | 2002-09-30 | 2011-09-28 | Zz Biotech L.L.C. | Protein s zur verwendung als neuroprotektives mittel |
| WO2004056309A2 (en) * | 2002-12-05 | 2004-07-08 | Socratech L.L.C. | Neuroprotective activity of activated protein c is independent of its anticoagulant activity |
| CA2508276C (en) * | 2002-12-05 | 2018-03-27 | Socratech L.L.C. | Neuroprotective activity of activated protein c is independent of its anticoagulant activity |
| US20070142272A1 (en) * | 2003-01-24 | 2007-06-21 | Zlokovic Berislav V | Neuroprotective activity of activated protein c independent of its anticoagulant activity |
| US9192657B2 (en) * | 2003-07-08 | 2015-11-24 | The Scripps Research Institute | Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity |
| US20080305100A1 (en) * | 2004-07-23 | 2008-12-11 | Zlokovic Berislav V | Activated Protein C Inhibits Undesirable Effects of Plasminogen Activator in the Brain |
| EP1841442A4 (de) * | 2005-01-07 | 2009-12-09 | Northern Sydney And Central Co | Behandlung von autoimmunkrankheiten und entzündlichen erkrankungen |
| US7785857B2 (en) * | 2006-08-31 | 2010-08-31 | Saint Louis University | Protein C variant |
| AU2008280782B2 (en) | 2007-07-20 | 2014-01-23 | Diamedica Inc. | Tissue kallikrein for the treatment of diseases associated with amyloid protein |
| US8257700B2 (en) * | 2008-02-05 | 2012-09-04 | The Board Of Trustees Of The Leland Stanford Junior University | Proteomic analysis of active multiple sclerosis lesions |
| US20120225051A1 (en) * | 2009-04-22 | 2012-09-06 | Sanomune Inc. | Tissue kallikrein for the treatment of huntington's disease |
| CA2877745C (en) | 2012-07-04 | 2021-11-30 | The University Of Sydney | Treatment of inflammatory skin disorders |
| CN104122396A (zh) * | 2013-04-23 | 2014-10-29 | 中国科学院上海生命科学研究院 | 维生素k依赖性蛋白s作为糖尿病标志物的应用 |
| WO2015157791A1 (en) | 2014-04-16 | 2015-10-22 | The University Of Sydney | Treatment of abnormal cutaneous scarring |
| JP6873387B2 (ja) | 2014-04-16 | 2021-05-19 | ジージー バイオテック エルエルシー | 創傷治癒に対するａｐｃ類似体の使用 |
| CN105806818B (zh) * | 2016-04-01 | 2019-11-22 | 南京医科大学 | 检测血小板nmda受体活性的方法及其应用 |
| EP3464322B1 (de) | 2016-06-05 | 2023-04-05 | Tel HaShomer Medical Research Infrastructure and Services Ltd. | Neuartige moleküle zur behandlung von entzündungen |
| US11857608B2 (en) | 2017-03-09 | 2024-01-02 | Diamedica Inc. | Dosage forms of tissue kallikrein 1 |
| TWI787767B (zh) | 2020-03-24 | 2022-12-21 | 大陸商深圳瑞健生命科學研究院有限公司 | 一種治療亨廷頓病的方法和藥物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5084274A (en) | 1987-11-17 | 1992-01-28 | Scripps Clinic And Research Foundation | Inhibition of arterial thrombotic occlusion or thromboembolism |
| US5009889A (en) * | 1987-12-31 | 1991-04-23 | Oklahoma Medical Research Foundation | Treatment of dysfunctional vascular endothelium using activated protein C |
| AT402153B (de) * | 1989-06-26 | 1997-02-25 | Immuno Ag | Protein-s-hältige pharmazeutische präparation |
| US5254532A (en) * | 1989-06-26 | 1993-10-19 | Immuno Aktiengesellschaft Fur Chemisch-Medizinische Produkte | Preparation for treating and preventing thromboses and thromboembolic complications, use of such a preparation and a method of producing the same |
| KR20010005626A (ko) * | 1997-03-24 | 2001-01-15 | 피터 지. 스트링거 | 혈관 질환의 치료 방법 |
| CA2293429A1 (en) * | 1997-06-05 | 1998-12-10 | Eli Lilly And Company | Methods for treating thrombotic disorders |
| HUP0001237A3 (en) * | 1997-10-20 | 2002-01-28 | Lilly Co Eli | Methods for treating vascular disorders |
-
2001
- 2001-02-05 DE DE60144366T patent/DE60144366D1/de not_active Expired - Lifetime
- 2001-02-05 EP EP01910427A patent/EP1255556B1/de not_active Expired - Lifetime
- 2001-02-05 AU AU2001238034A patent/AU2001238034A1/en not_active Abandoned
- 2001-02-05 JP JP2001556226A patent/JP2004508280A/ja active Pending
- 2001-02-05 US US09/777,484 patent/US7074402B2/en not_active Expired - Fee Related
- 2001-02-05 WO PCT/US2001/003758 patent/WO2001056532A2/en active Application Filing
- 2001-02-05 CA CA2398929A patent/CA2398929C/en not_active Expired - Fee Related
- 2001-02-05 AT AT01910427T patent/ATE504310T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1255556A4 (de) | 2003-07-02 |
| CA2398929C (en) | 2011-05-31 |
| CA2398929A1 (en) | 2001-08-09 |
| ATE504310T1 (de) | 2011-04-15 |
| EP1255556A2 (de) | 2002-11-13 |
| AU2001238034A1 (en) | 2001-08-14 |
| US7074402B2 (en) | 2006-07-11 |
| US20020028199A1 (en) | 2002-03-07 |
| EP1255556B1 (de) | 2011-04-06 |
| WO2001056532A2 (en) | 2001-08-09 |
| WO2001056532A3 (en) | 2001-12-06 |
| JP2004508280A (ja) | 2004-03-18 |
| WO2001056532A9 (en) | 2003-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60144366D1 (de) | Neuroprotektive, antithrombotische und anti-entzündliche anwendungen von aktiviertem protein c | |
| ATE450269T1 (de) | Peptid pyyä3-36ü zur behandlung von stoffwechselkrankheiten | |
| KR960704839A (ko) | β-아밀로이드 단백질 생성 억제제(Inhibitors of β-amyloid protein production) | |
| BR0314721A (pt) | Compostos tricìclicos úteis para tratamento de distúrbios inflamatórios e alérgicos, processo para sua preparação e composições farmacêuticas contendo-os | |
| WO2004110387A3 (en) | Sigma ligands for neuronal regeneration and functional recovery | |
| CY1111359T1 (el) | Μεμαντινη για την θεραπεια ηπιας εως μετριας ασθενειας alzheimer | |
| ATE355374T1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
| EA200501560A1 (ru) | Предотвращение и терапия амилоидогенной болезни | |
| ATE411813T1 (de) | Behandlungen mit botulinum toxin von neurologische und neuropsychiatrische krankheiten | |
| MXPA03010843A (es) | Uso de derivados con azetidinona en el tratamiento de enfermedad de alzheimer. | |
| HUP0100786A2 (hu) | Helyettesített 2-fenil-1-(3,4-dihidroxi-5-nitrofenil)-1-etanonok, felhasználásuk egyes központi és perifériás idegrendszeri betegségek kezelésére és e vegyületeket tartalmazó gyógyszerkészítmények | |
| WO2006001877A3 (en) | Combination treatment for neurodegenerative disorders comprising r-flurbiprofen | |
| BRPI0313792B8 (pt) | utilização de proteína de eritropoetina, método para tratamento de distúrbios de distribuição de ferro em diabetes e medicamento para o seu tratamento | |
| EP1251126A3 (de) | Fluor-substituierte benzensulfonyl-derivate zur behandlung von entzündungen | |
| DK1272208T3 (da) | Anvendelse af VEGF 165 og homologer til at behandle neuron-sygdomme | |
| WO2008066626A3 (en) | METHODS FOR THE TREATMENT OF Aβ RELATED DISORDERS AND COMPOSITIONS THEREFOR | |
| WO2007053580A3 (en) | Sigma ligands for neuronal regeneration and functional recovery | |
| WO1999048489A3 (en) | Melatonin for delaying the onset of alzheimer's disease and for treating or delaying the onset of other amyloidosis-related diseases/disorders | |
| BR0314713A (pt) | Processos e reagentes para o tratamento de doenças e distúrbios associados com nìveis aumentados de citocinas pró-inflamatórias | |
| WO2005046605A3 (en) | Compositions and methods of treating neurological diseases | |
| WO2010036813A8 (en) | Materials and methods for preventing or treating neurodegenerative conditions associated with abeta peptide accumulation | |
| WO2006002096A3 (en) | Low doses of l-citrulline for treating diseases | |
| EA200702534A1 (ru) | Применение бензоильного производного 3-аминокарбазола для лечения расстройства, связанного с продукцией простагландина e2(pge2) | |
| WO2002076437A3 (en) | Methods for treating neurodegenerative diseases including alzheimer's | |
| EP1365771A4 (de) | Verfahren zur behandlung bestimmter augenkrankheiten |